Patients harboring BRCA1/2 or PALB2 mutations may benefit from platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors (21), whereas those with MMR deficiency may be eligible for immune checkpoint inhibitor therapy (22). This evidence concerns the gene PALB2 and mismatch repair cancer syndrome 1.